MegaPro Biomedical Co., Ltd.'s main product is mainly the nano iron oxide.
Based on the core team that developed nano-iron oxide products in the Industrial Technology Research Institute, the company is established to focus on the development of niche-type nano drugs. Since the company is positioned as a technology company with nanoparticles and nanocells as the core technology, the industry chain is positioned to add value in the pre-clinical human clinical and early human pre-clinical clinical trials, so it does not intend to establish manufacture for mass production of drugs but to seek partnership with domestic APIs and preparation plants to provide sources of drugs for clinical trials. After confirming the efficacy of drugs through clinical trials, we actively seek joint development or authorization with domestic or international pharmaceutical companies. Therefore, it is a lightly-equipped company. After the completion of clinical work, the company plans to develop the market jointly with strategic partners and carries out product authorization and technology development as the initial profit model of the company. Such a business model strategy should be the most appropriate choice in strengthening the level of division of labor in Taiwan's biomedical industry and enhancing the technical and commercial strength of the overall biomedical industry (CMO, CRO, testing and other secondary industries).
After the successful development of the first few drug candidates, for the company's sustainable operation and the implementation of Taiwan's nano drug research and development achievements, the company also hopes that it will become an outlet for Taiwan's nano drug research and development, continue to introduce pre-clinical drug candidates with development potential, and establish a sustainable company.